Atossa Therapeutics, Inc. cash flow statement

In fiscal 2015, Atossa Therapeutics, Inc.'s operations generated −$14.0m of cash.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atossa Therapeutics, Inc.: cash flow statement, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	LTMSept 2016
Cash from operations	−3	−4	−9	−11	−14	−8
Depreciation and amortisation	0	0	0	0	0	0
Stock-based pay	0	0	1	1	1	1
Shares issued	—	—	—	13	9	5

US$ thousands unless shown otherwise. Fiscal quarters.

Atossa Therapeutics, Inc.: cash flow statement, quarterly
Quarter	2014 Q4Dec 2014	2015 Q1Mar 2015	2015 Q2Jun 2015	2015 Q3Sept 2015	2015 Q4Dec 2015	2016 Q1Mar 2016	2016 Q2Jun 2016	2016 Q3Sept 2016
Cash from operations	−2,719	−2,999	−3,521	−3,481	−3,953	−2,995	−1,659	635
Depreciation and amortisation	99	64	13	33	104	76	33	30
Stock-based pay	11	149	205	318	206	192	200	257
Shares issued	0	4,292	5,211	−5	−42	2,167	−33	2,562

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atossa Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atossa Therapeutics, Inc.